Updated: Crescendo rolls out iPhone app for RA Dx

Crescendo Bioscience unveiled an iPhone app as a new resource for patients. The free app, dubbed MyRA, is designed to also run on an iPad or iPod touch device and is intended help patients track their RA daily. Crescendo is known separately for Vectra DA, the company's RA blood test that measures 12 different immune endothelial, bone, cartilage and metabolic biomarkers common to the disease. The diagnostic then measures concentrations of those biomarkers from a scale of 1 to 100. Crescendo secured $28 million in new Series D financing in January 2013, money designed to help the company boost its commercialization efforts for Vectra DA. Release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.